Relay Therapeutics May 2023 Corporate Presentation

Note: Single experiment that tested each compound run at 500nM against 468 targets in the absence of ATP and without preincubation Source: KINOMEscan™ by Eurofins DiscoverX © 2023 Relay Therapeutics RLY-4008 – ReFocus Trial Design RLY-4008 RP2D: 70 mg QD Data from 2022 ESMO Congress (September 2022) 1. Efficacy analysis includes patients with previously treated, FGFR2i-naïve CCA treated at the RP2D. Patients with measurable disease who had opportunity for ≥2 tumor assessments to confirm response or disconti ...